weight loss glp-1 agonists Which Agonist is Best for Loss? Balancing weight and muscle loss

Phase 2 trial results (48 weeks, adults with obesity): 1 mg dose: 7.2% body weight loss 4 mg dose: 12.9% body weight loss 8 mg dose: 17.3% body weight loss 12 mg dose: 24.2% body weight loss Placebo: 1.6% body weight loss Phase 3 TRIUMPH-4 results: 9 mg dose: 20.0% body weight loss (22.9 kg / 50.5 lbs) 12 mg dose: 23.7% body weight loss (27.2 kg / 60.0 lbs) Placebo: 4.6% body weight loss In a separate phase 3 analysis, retatrutide at the highest dose achieved up to 28.7% weight loss

75% of prescriptions linked to supplements were GP-guided in 2025

Understanding the Danger of Chronic Dehydration Over time, not taking in enough fluid can have a serious negative impact on health

However patient discontinuation due to adverse effects from treatment was between 18% and 32% for all Efinopegdutide doses, and 17% for Liraglutide [4]

To read a deeper analysis of these risk factors and how they compare to the metabolic benefits of incretin therapy, read Weight Loss Wonders or Risk Factors: A Deep Dive into Incretin Therapy and the comprehensive paper on Adverse Effects of GLP-1 Receptor Agonists PMC